mozobil solución inyectable 20 mg/ml
laboratorio genzyme chile ltda. - plerixafor - sin formulas
celixafor
laboratorio varifarma s.a. argentina - plerixafor: 20,0 mg/ml - solucion inyectable - cada ml de solución inyectable contiene: plerixafor: 20,0 mg/ml
revixil 20
gador s.a. argentina - plerixafor 20mg - solucion inyectable - cada ml contiene: plerixafor 20mg
mozobil 20 mg/ml 1 vial 1,2 ml
revixil 20 solución inyectable
gador - solución inyectable - plerixafor 24 mg/1.2 ml (20 mg/ml) inyectable
neofordex
theravia - dexametasona - mieloma múltiple - corticosteroides para uso sistémico - tratamiento del mieloma múltiple.
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - otras drogas del sistema nervioso - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.
darzalex
janssen-cilag international n.v. - daratumumab - mieloma múltiple - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. en combinación con bortezomib, la talidomida y dexametasona para el tratamiento de pacientes adultos con diagnóstico reciente de mieloma múltiple, que son elegibles para el trasplante autólogo de células madre. en combinación con lenalidomida y dexametasona, o bortezomib y dexametasona para el tratamiento de pacientes adultos con mieloma múltiple que han recibido al menos una terapia previa. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. como monoterapia para el tratamiento de pacientes adultos con recaída y refractarios mieloma múltiple, cuya antes de la terapia incluye un inhibidor del proteasoma y un agente inmunomodulador y que han demostrado que la progresión de la enfermedad en la última terapia. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.
laxafor solución inyectable 20 mg/ ml
seven pharma chile s.p.a. - plerixafor - sin formulas
glixafor 10 10 mg tableta recubierta
seven pharma s.a.c. - droguerÍa - tableta recubierta - por tableta - - dapagliflozina